Disorders of the Peripheral Nervous System

Living reference work entry

Abstract

Disorders of the peripheral nervous system are caused by a variety of diseases, toxins, trauma, and metabolic causes. Neuropathies are estimated to affect 2–8 % of the population with the incidence being higher in older individuals [1]. Depending on the cause a single or multiple nerves may be involved. The most common causes of polyneuropathy are diabetes, alcoholism, fatty liver disease, and malignancy.

Keywords

Vasculitis Homocysteine Amiodarone Thiamine Sarcoidosis 

References

  1. 1.
    Martyn CN. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310–18.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Latinovic R. Incidence of common compressive neuropathies in primary care. J Neurol Neurosurg Psychiatry. 2006;77:263–5.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Willison HJ. Clinical evaluation and investigation of neuropathy. J Neurol Neurosurg Psychiatry. 2003;74 Suppl 2:ii3–8.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Zandian A. The neurologist’s dilemma: a comprehensive clinical review of Bell’s palsy, with emphasis on current management trends. Med Sci Monit. 2014;20:83–90.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Baugh RF. Clinical practice guideline: Bell’s palsy executive summary. Otolayrngology. 2013;149(5):656–63.Google Scholar
  6. 6.
    Salinas RA. Corticosteroids for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2010;3.Google Scholar
  7. 7.
    Lockhart P. Antiviral treatment for Bell’s palsy. Cochrane Database Syst Rev. 2009;4.Google Scholar
  8. 8.
    Merskey H. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press; 1994. p. 59–71.Google Scholar
  9. 9.
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 3rdd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRefGoogle Scholar
  10. 10.
    Gronseth G. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review). Neurology. 2008;71:1183–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Patijn J. Carpal tunnel syndrome in evidence-based interventional pain medicine according to clinical diagnoses. Pain Pract. 2011;11(3):297–301.CrossRefPubMedGoogle Scholar
  12. 12.
    Kaymak B. A comparison of the benefits of sonography and electrophysiologic measurements as predictors of symptom severity and functional status in patients with carpal tunnel syndrome. Arch Phys Med Rehabil. 2008;89:743–8.CrossRefPubMedGoogle Scholar
  13. 13.
    American Academy of Orthopedic Surgeon’s Work Group Panel. Clinical practice guideline on the treatment of carpal tunnel syndrome. AAOS. 2008. http://www.aaos.org/Research/guidelines/CTSTreatmentGuideline. Accessed Jan 30, 2015.
  14. 14.
    Rinkel WD. Current evidence for effectiveness of interventions for cubital tunnel syndrome, radial tunnel syndrome, instability, or bursitis of the elbow: a systematic review. Clin J Pain. 2013;29:1087–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Dang AC. Unusual compression neuropathies of the forearm, part I: radial nerve. J Hand Surg. 2009;34A:1906–14.CrossRefGoogle Scholar
  16. 16.
    Arnold WD. Prognosis of acute compressive radial neuropathy. Muscle Nerve. 2012;45:893–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Bsteh G, Wanschitz JV, Gruber H, Seppi K, Löscher WN. Prognosis and prognostic factors in non-traumatic acute-onset compressive mononeuropathies – radial and peroneal mononeuropathies. Eur J Neurol. 2013;20:981–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Cheatham SW. Meralgia paresthetica: a review of the literature. Int J Sports Phys Therapy. 2013;8:883–93.Google Scholar
  19. 19.
    Stewman C. Neurologic thoracic outlet syndrome: summarizing a complex history and evolution. Curr Sports Med Rep. 2014;13:100–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Aval SM. Neurovascular injuries to the athlete’s shoulder: part 1. J Am Acad Orthop Surg. 2007;15(4):249–56.PubMedGoogle Scholar
  21. 21.
    Feinberg JH. Paronsage-Turner syndrome. HSS J. 2010;6:199–205.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Tarulli A. Lumbosacral plexitis. J Clin Neuromusc Dis. 2005;7:72–8.CrossRefGoogle Scholar
  23. 23.
    Johnson RW. Postherpetic neuralgia. N Engl J Med. 2014;271:1526–33.Google Scholar
  24. 24.
    Freitas MR. Infectious neuropathy. Curr Opin Neurol. 2007;20:548–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Seretny M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Smith, EML for the Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309: 1359–67Google Scholar
  27. 27.
    Rinaldi S. Update on Guillain-Barre syndrome. J Peripher Nerv Syst. 2013;18:99–112.CrossRefPubMedGoogle Scholar
  28. 28.
    Cortese I. Evidence-based guideline update: plasmapheresis in neurologic disorders. Neurology. 2011;76:294–300.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Hughes AC. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;9.Google Scholar
  30. 30.
    Bright RJ. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. BMC Neurol. 2014;14:26.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Bril V. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology. Neurology. 2011;76(20):1758–65.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Krishnan AV. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve. 2007;35(3):273–90.CrossRefPubMedGoogle Scholar
  33. 33.
    Hammond N. Nutritional neuropathies. Neurol Clin. 2013;31(2):477–89.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Jerath NU. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Ciochim Ciophys Acta. 2015;1852(4):667–78.Google Scholar
  35. 35.
    National Institute for Health and Care Excellence (NICE). Neuropathic pain – pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings. 2013 Nov. (Clinical guideline; no. 173)Google Scholar
  36. 36.
    Wiffen PJ. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;12.Google Scholar
  37. 37.
    Liu J. Pharmacological treatment for pain in Guillain-Barre syndrome. Cochrane Database Syst Rev. 2013;10.Google Scholar
  38. 38.
    McNicol ED, editor. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;9.Google Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2015

Authors and Affiliations

  1. 1.Family Medicine ResidencyDavid Grant Medical CenterTravis AFBUSA

Personalised recommendations